RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut
Yahoo Finance ·
RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut Bailey Pemberton Sat, July 25, 2026 at 4:06 PM EDT 3 min read RXST BAC ALC Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. RxSight's latest valuation work has taken the modelled fair value from US$9.93 to US$8.43, which points to a refreshed view of what the stock may be worth under updated assumptions. Analysts are linking this reset to softer recent Q2 trends, revised guidance, and the timing of potential contributions from the new Alcon collaboration. As you read on, you will see how these moving parts are shaping the evolving RxSight story and what to watch next in the analyst narrative. Stay updated as the Fair Value for RxSight shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on RxSight. Both Jefferies and BofA still see a case for RxSight's technology, with BofA highlighting that the new Alcon collaboration could expand the company's reach into light adjustable PCIOLs where it is not active today. BofA notes that the Alcon partnership allows RxSight to leverage its LAL technology across a broader product set. Some investors may view this as a longer term source of potential growth once products from the collaboration are commercialized. Jefferies cut its RxSight price target from US$7.50 to US$6.50 and kept a Hold rating after preliminary Q2 results came in below expectations, pointing to competitive trialing and macro pressures and to utilization at a four year low. BofA lowered its RxSight price target from US$8 to US$6.50 and maintained an Underperform rating after preliminary Q2 sales of US$27m versus Street expectations of US$32m, a guidance cut of US$13m at the midpoint for 2026, and management commentary about elevated competitive trialing and softer consumer sentiment. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives! We've flagged 2 risks for RxSight. See which could impact your investment. Fair value moved from US$9.93 to US$8.43. Assumed revenue growth moved from 5.22% to 8.76%. Expected net profit margin shifted from 12.79% to 11.76%. Future P/E multiple moved from 26.74x to 22.78x. The discount rate eased from 7.85% to 7.45%. Narratives connect RxSight's business story to a set of financial assumptions and a fair value estimate that move as new data comes in. They give you a single place to track how catalysts and risks are shaping the investment case over time. Head over to the Simply Wall St Community and follow the Narrative on RxSight to stay up to date on: How RxSight's realigned sales, clinical support, and customer success teams, together with new education efforts, aim to lift LAL adoption and utilization from the existing installed base. Progress on international expansion into newly approved European and Asian markets, along with investments in clinical affairs and surgeon training to support adoption. Key risks related to heavy reliance on LALs for roughly 80% of revenue, rising SG&A and R&D costs, and regulatory or reimbursement headwinds that could affect growth and margins. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include RXST . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
DYAX Investor Sentiment
Bullish (Long) 46% · Bearish (Short) 54%
518 participants
Related News
- CoreWeave Stock Fell 11.4% on Friday. The Sell-Off Is About What It's Spending, Not What It's Selling.
- NuScale Power Is Down 38% This Year: Here's What the Next 5 Years Could Look Like
- Houthis attack two Aramco oil sites as US holds off on nightly bombing of Iran
- Warner Bros. lawsuit accuses Amazon of illegally poaching executives
- The Simplest Way to Invest in the AI Revolution Is Hiding in Plain Sight
- UCOP: A 2X Bet on the Metal the World Can’t Electrify Without
